Ovarian highlights from ESMO 2019
Ovarian highlights from ESMO 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC
Comment: Osimertinib for EGFR-mutation positive NSCLC
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients
First results of the GMMG-CONCEPT trial for multiple myeloma
Iberdomide in combination with dexamethasone for multiple myeloma